ABSTRACT Hemodynamic effects of dopamine and intravenous nitroglycerin alone, and in combination, were studied in 27 patients with severe left ventricular failure. Dopamine alone increased cardiac index from 1.8 to 2.5 1/min/m2 but also increased wedge pressure from 24 to 30 mm Hg and heart rate from 88 to 101 beats/min. Arterial oxygen saturation fell from 92% to 87% (p < .001). Nitroglycerin alone had a lesser effect on cardiac index (1.8 to 2.2 1/min/m2) but decreased wedge pressure from 26 to 16 mm Hg and heart rate from 91 to 86 beats/min. Arterial oxygen saturation fell from 91% to 90% (NS). Combined dopamine and nitroglycerin administration resulted in optimal hemodynamics, with cardiac index of 2.9 1/min/m2, wedge pressure of 17 mm Hg, and heart rate of 96 beats/min. Arterial oxygen saturation remained low at 88% in spite of the reduction in left ventricular filling pressure, which probably reflects increased intrapulmonary right-to-left shunting coupled with increased pulmonary blood flow. These results suggest that the combination of dopamine with intravenous nitroglycerin should be considered for patients with severe left ventricular dysfunction who require temporary pharmacologic support. Circulation 68, No. 4, 813-820, 1983. TEMPORARY pharmacologic support of patients with chronic severe left ventricular dysfunction is frequently required either during episodes of deterioration or before definitive diagnostic or therapeutic procedures. Although a variety of intravenous inotropic and vasodilator drugs are available for this purpose, the selection of a specific drug or combination of drugs remains largely empiric.
TEMPORARY pharmacologic support of patients with chronic severe left ventricular dysfunction is frequently required either during episodes of deterioration or before definitive diagnostic or therapeutic procedures. Although a variety of intravenous inotropic and vasodilator drugs are available for this purpose, the selection of a specific drug or combination of drugs remains largely empiric.
Dopamine, a catecholamine with significant inotropic activity, has potential advantages for use in patients with advanced low-output cardiac failure because of its selective effect on promoting blood flow to renal and splanchnic beds via stimulation of nonadrenergic vasodilator receptors in these areas. 1 Although dopamine infusion may reduce an elevated left ventricular filling pressure in some patients with heart failure, other patients may show a significant increase in filling pressure associated with the development of pulmonary congestion or edema.2' 3 The possible mechanisms of dopamine-induced elevation of left ventricular filling pressure, particularly at higher doses, are many and include increased preload and afterload due to excessive a-receptor-mediated vasoconstriction, excessive tachycardia, and/or myocardial ischemia in patients with severe coronary artery disease. In addition, in patients with chronic heart failure, the inotropic response to dopamine may be diminished by prior myocardial catecholamine depletion4 or by "down regulation" of myocardial fl-receptors secondary to prolonged compensatory sympathetic stimulation.' In such patients the high doses of dopamine required to obtain an adequate inotropic effect may be associated with excessive and undesirable a-receptor stimulation.
Nitrates have been shown to be effective venodila- tors 6 iig/kg/min frequently lead to undesirable tachy-814 cardia and/or elevation of arterial pressure when given to patients with advanced cardiac failure. Nitroglycerin was started at 20 Aug/min with increases of 20 ;g/min every 2 min until WP fell bymore than or equal to 50%, ASP fell by more than 20mm
Hg, HR was greater than 120 beats/min, or a maximal dose of 400,ug/min was given. This maximal dose of nitroglycerin is considerably higher than that commonly used for the treatment of patients with unstable angina, and it seems unlikely that doses above 400,ug/min would have resulted in significant additional hemodynamic improvement. Measurements were made during a steady state 15 min after final dose adjustment.
After measurements had been completed, the first drug infusion was stopped and control measurements were made after 15 min.
The second drug was then evaluated in similar fashion. Studies were then repeated during combined drug administration at full dose of drug 2 plus a half dose of drug 1, a full dose of both drugs, and a half dose of drug 2 plus a full dose of drug 1.
Statistical analysis was performed with Student's t test for paired numerical data. Both dopamine and nitroglycerin infused alone at full doses were compared with respective control values obtained immediately before the infusions (table 1) . Dopamine alone at full dose was compared with a full dose of dopamine combined with a half dose and a full dose of nitroglycerin, and nitroglycerin alone at a full dose was compared with a full dose of nitroglycerin combined with a half dose and a full dose of dopamine (table 2) .
Results
Effects of dopamine and nitroglycerin alone ( AVO2z, while both systemic and right-sided pressures were similar. When compared with a full dose of nitroglycerin alone, combined nitroglycerin and dopamine at full doses yielded significantly higher mean values for ASP, CI, SI, and LVSWI, and lower mean values for SAR, PAR, and AVO2A, while MAP, ADP, and right-sided pressures were not increased. The ART 02 of 88% during nitroglycerin plus dopamine was significantly less (p < .02) than the mean value of 90% during nitroglycerin alone.
Discussion
The desired hemodynamic goals of short-term intravenous drug therapy in patients with advanced lowoutput cardiac failure includes augmentation of forward output and peripheral perfusion plus reduction in backward failure and pulmonary congestion. An additional important goal, particularly in patients with coronary disease, is the maintenance of an adequate coronary perfusion pressure and avoidance of myocardial ischemia. Of the inotropic drugs available for continuous intravenous infusion, both dobutamine and dopamine have been shown to significantly augment CO in patients with advanced heart failure. However, when these drugs are used alone, an elevated left ventricular filling pressure may fall only slightly or, in the case of dopamine, may actually increase.2' Additionally, both dobutamine and dopamine may increase net myocardial oxygen demand unless preload and myocardial wall tension are concurrently reduced sufficiently to offset the direct inotropic and chronotropic actions of these drugs.
As an alternative to inotropic therapy, intravenous vasodilators have become popular for short-term man-816 agement of patients with severe left ventricular failure. Sodium nitroprusside, which acts on both the venous and arterial systems,'0 has been shown to result in significantly lower WP and HR when compared with dobutamine at doses that augmented CO to the same extent."' 12 11 Recently, intravenous nitroglycerin has become commercially available; however, its role in the management of patients with severe left ventricular failure has yet to be defined. Theoretically nitroglycerin may offer certain advantages over nitroprusside, particularly when used in combination with inotropic drugs. Its more potent action on venous vs arterial smooth muscle'3 should make it possible to effectively reduce preload without causing excessive hypotension, which could compromise coronary and peripheral perfusion. Nitroglycerin dilates the large conduit CIRCULATION coronary vessels'4, 15 and may augment flow to areas supplied by stenotic coronary vessels'6; this is in contrast to nitroprusside, which dilates coronary resistance vessels and may reduce flow to ischemic myocardium. 17 Additionally, prolonged nitroprusside administration may cause accumulation of toxic levels of thiocyanate, IB whereas intravenous nitroglycerin can be given safely for extended periods. '3 Leier et al.9 compared intravenous nitroglycerin with nitroprusside in 10 patients with congestive failure. At doses that exerted a similar reduction in left ventricular filling pressure, nitroprusside resulted in a greater increase in CO and reduction in arterial pressure than did nitroglycerin. Effects on limb and hepatic blood flow were similar and renal blood flow, which fell significantly during nitroglycerin treatment, was unchanged with nitroprusside. Thus, although intravenous nitroglycerin is well tolerated and is very effective in reducing elevated pulmonary and left-sided filling pressures in patients with severe acute or chronic heart failure, it is generally less effective than inotropic drugs or sodium nitroprusside in augmenting CO and systemic blood flow.
To achieve optimal hemodynamic effects, combined intravenous therapy with inotropic and vasodilator drugs has been advocated. The combination of dobutamine with nitroprusside, 1l 19 20 dobutamine with nitroglycerin,2' and dopamine with nitroprusside22' 23 or sublingual isosorbide dinitrate24 have each been reported to result in more favorable hemodynamics than achieved with the inotropic or vasodilator drugs administered separately.
Our experience with 27 patients with severe lowoutput cardiac failure clearly demonstrated that the combination of intravenous nitroglycerin with dopamine resulted in major hemodynamic improvement not obtainable with either drug used alone. Figure 1 shows that dopamine increased both systemic and right-sided pressures. WP increased in two-thirds of our patients from a mean of 24 to adrenergic-mediated renal and mesenteric vasodilator properties' that might be highly desirable in patients with low-output states and reduced renal blood flow.
As can be seen in figure 1 , the combined use of intravenous nitroglycerin with dopamine markedly reduced the high WP and right-sided pressures to levels essentially the same as with nitroglycerin alone. Arterial pressures, although also reduced, remained well above hypotensive levels. Therefore, nitroglycerin would seem to have advantages over nitroprusside in patients with borderline hypotension. The fact that intravenous nitroglycerin resulted in major reduction of left ventricular filling pressure, pulmonary artery pressure, and RAP with only a modest fall in systemic arterial pressure probably reflects the greater relative effect nitroglycerin has on venous vs arterial smooth muscle, and to some extent distinguishes it from most other vasodilators used for treatment of patients with heart failure. Since patients with 817 70> L w advanced heart failure have a depressed Starling function curve, CO will be minimally affected by even large changes in preload. Nitroglycerin, therefore, would not be expected to markedly lower systemic and coronary perfusion pressures in such patients. To the contrary, reduction of elevated intracavitary diastolic pressures could augment subendocardial perfusion, and reduction in wall tension should reduce myocardial oxygen demand with a net effect of improving the myocardial oxygen supply and demand relationship. Although the hemodynamic responses we observed are compatible with these concepts, we did not measure myocardial blood flow or oxygen consumption in our patients, nor was it possible from clinical or electrocardiographic observations to demonstrate effects of the drugs alone or in combination on the relationship between myocardial oxygen supply and demand. Such studies should be undertaken in the future.
In figure 2 , changes in HR, CI, SI, and resistances are illustrated. During single drug administration, dopamine was more effective than nitroglycerin in augmenting CO; however, the maximal increases in The overall effect of the infusions on left ventricular performance is shown in figure 3 , which is a plot of left In a previous study,3 we compared the hemodynamic effects of dopamine with those of dobutamine in patients with severe chronic heart failure. We observed a fall in ART 02 during dopamine infusion in association with elevation of WP to above 30 mm Hg. Although increased CO per se may result in arterial hypoxemia by increasing flow to nonventilated or poorly ventilated lungs,29' 30 ART 02 did not fall during dobutamine infusion in spite of similar increases in CO. In view of this, plus the fact that WP rose with dopamine but not with dobutamine, we felt that pulmonary congestion best explained the arterial hypoxemia we observed during dopamine infusion.
In the present study, we again observed a significant reduction in ART 02 from 92% to 87% during dopamine infusion. Of 25 patients in whom ART 02 was measured immediately before and during dopamine infusion, 12 had a reduction in ART 02 of 5% or more. Comparing these 12 patients with the remaining 13 patients (figure 4), it was again apparent that as a group the patients having the greatest fall in ART 02 during dopamine infusion had higher mean values for left 
